AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Voltage-dependent calcium channel subunit alpha-2/delta-1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for ion channels.

 Fig. 1. The sreening workflow of Receptor.AI

It includes extensive molecular simulations of the channel in its native membrane environment in open, closed and inactivated forms and the ensemble virtual screening accounting for conformational mobility in each of these states. Tentative binding pockets are considered inside the pore, in the gating region and in the allosteric locations to cover the whole spectrum of possible mechanisms of action.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P54289

UPID:

CA2D1_HUMAN

Alternative names:

Voltage-gated calcium channel subunit alpha-2/delta-1

Alternative UPACC:

P54289; Q17R45; Q9UD80; Q9UD81; Q9UD82

Background:

The Voltage-dependent calcium channel subunit alpha-2/delta-1, also known as Voltage-gated calcium channel subunit alpha-2/delta-1, plays a pivotal role in regulating calcium current density and the activation/inactivation kinetics of calcium channels. Its involvement in excitation-contraction coupling underscores its importance in cellular signaling and muscle contraction.

Therapeutic significance:

Linked to Developmental and epileptic encephalopathy 110, a condition characterized by severe developmental delay, hypotonia, and early-onset seizures, the alpha-2/delta-1 subunit's dysfunction highlights its potential as a therapeutic target. Understanding its role could lead to novel treatments for this debilitating disease.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.